ArticleComputational and structural biotechnology journal2026
seneR: An R package for comprehensive senescence assessment and its application in type 2 diabetes and osteoarthritis.
Article in Computational and structural biotechnology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cellular senescence is a key driver of aging and chronic diseases. However, accurately identifying senescent cells is challenging due to limitations of conventional biomarkers and senescence heterogeneity. Transcriptome-wide analyses offer powerful tools for deciphering cellular states. Yet, there is a critical gap in computational frameworks for senescence assessment from transcriptomic data. Methods: We developed the seneR package, which includes functions such as calculating senescence identity scores (SID scores), assessing senescence-related phenotypes, and plotting senescence trajectories, and provides an interactive Shiny interface. We applied seneR to transcriptome datasets from human islets and chondrocytes to investigate the role of senescence in Type 2 Diabetes (T2D) and osteoarthritis (OA). Additionally, in vitro validation confirmed phentolamine (PM)'s potential to delay chondrocyte senescence. Results: seneR accurately identified senescent cells and revealed senescence-related phenotypes in transcriptome datasets. In T2D, SID scores were significantly higher in elderly islets. Senescent islet cells exhibited diminished responsiveness to nutrient stimuli, linking senescence to impaired insulin secretion. In OA, seneR identified SLPI as a molecule strongly associated with chondrocyte senescence, with PM treatment reducing SID scores. Trajectory analysis revealed chondrocyte senescence progression and potential therapeutic targets. In vitro experiments, PM reversed both IL-1β- and H₂O₂-induced chondrocyte senescence. Conclusion: Our study demonstrates that seneR is a valuable tool for assessing cellular senescence from transcriptomic data, revealing key phenotypes and potential therapeutic targets in T2D and OA. The identification of SLPI as a senescence-associated molecule and the therapeutic potential of PM highlights the utility of our approach in understanding senescence-related diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.